Celularity Launches cenplacel-L Cell Therapy in Florida
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Celularity and Fountain Life announced the availability of cenplacel-L, a placental-derived allogeneic investigational cell therapy, for investigational use by licensed physicians in the State of Florida under recently enacted legislation supporting responsible use of regenerative medicine.The company said, "This milestone marks the establishment of one of the first state-level frameworks in the United States enabling the physician-directed use of allogeneic cellular therapies outside of traditional federal approval pathways, creating a potential model for broader market expansion. Celularity is uniquely positioned to support this opportunity through its FDA-registered, GMP-compliant manufacturing infrastructure and existing inventory of clinical-grade product, enabling near-term clinical deployment. Celularity maintains a robust inventory of cenplacel-L at its FDA-registered, GMP-compliant manufacturing facility and is prepared to support physician-directed investigational use consistent with the requirements of Florida law."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CELU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CELU
About CELU
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Its IMPACT manufacturing platform is a fully integrated process designed to optimize the speed of the sourcing of placentas from full-term healthy informed consent donors through the use of proprietary processing methods, cell selection, product-specific chemistry, manufacturing and control (CMC), advanced cell manufacturing and cryopreservation. It also provides contract manufacturing and development services to third parties.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Celularity Receives Nasdaq Notice for Late Q1 2026 Filing
- Nasdaq Notice: Celularity received a Nasdaq notice for failing to timely file its Q1 2026 Form 10-Q, resulting in non-compliance with listing rules, although its stock continues to trade on Nasdaq.
- Compliance Plan Window: The company has a 60-day window until July 28 to submit a plan to regain compliance, and if accepted by Nasdaq, it may receive an extension of up to 180 days, with a final deadline around November 16, 2026.
- Proactive Measures: Celularity states it is actively working to file the delayed report and restore full compliance, indicating the company's commitment to addressing compliance issues.
- Stable Market Reaction: Despite facing compliance challenges, Celularity's stock has not experienced immediate impact in Nasdaq trading, reflecting market confidence in its future compliance plans.
See More
U.S. Stocks Rise Modestly; Three Stocks to Watch
- Market Performance: U.S. stocks rose modestly on the first trading day of May, with the S&P 500 gaining 0.3% to close above 7,200 for the first time, reflecting investor optimism despite a 0.3% dip in the Dow.
- Cantaloupe Stock Movement: Cantaloupe (CTLP) shares rose 1.6% in after-hours trading following the FTC's approval of 365 Retail's planned $848 million acquisition, which includes a required divestiture, potentially strengthening its market position.
- Celularity Stock Recovery: Celularity (CELU) shares gained 4.5% after regaining Nasdaq compliance, which is expected to boost investor confidence and attract more capital inflows into the company.
- Universal Logistics Earnings Miss: Universal Logistics (ULH) shares dipped 1.4% in extended trading after reporting Q1 GAAP EPS of -$0.13, missing consensus by $0.22, and operating revenue of $367.6 million, which fell short by $4.7 million, indicating operational challenges ahead.
See More
Celularity Regains Nasdaq Compliance with 10-K Filing
- Compliance Restoration: Celularity's filing of its 10-K annual report for the year ended December 31, 2025, has restored its compliance with Nasdaq listing rules, marking a significant advancement in the company's financial transparency and boosting investor confidence.
- Strategic Transformation Progress: CEO Robert Hariri noted that this filing represents an important milestone in the company's strategic transformation, reflecting positive developments in portfolio realignment and cost reductions aimed at enhancing overall operational efficiency.
- Financial Burden Reduction: By reducing liabilities by approximately $13 million, Celularity has further solidified its financial position, which will help the company focus resources on its core cell therapy and longevity programs, driving future growth.
- Personnel Adjustments: The company has also implemented personnel reductions to optimize human resource allocation, enhancing operational efficiency to maintain competitiveness in the highly competitive biotechnology sector.
See More
Celularity Regains Nasdaq Compliance After 10-K Filing
- Compliance Restoration: Celularity has successfully regained compliance with Nasdaq listing rules after filing its Form 10-K, ensuring the continued trading eligibility of its stock and avoiding potential delisting risks.
- Increased Financial Transparency: By submitting the 10-K, Celularity has enhanced the transparency of its financial reporting, boosting investor confidence and potentially attracting more investor interest in its future developments.
- Positive Market Reaction: The news of compliance restoration is likely to have a positive impact on Celularity's stock price, reinforcing market confidence in its business model and long-term growth potential.
- Strategic Implications: This compliance restoration not only secures the company's stable position in the capital markets but also provides more favorable conditions for future financing and business expansion.
See More
Celularity Regains Nasdaq Compliance with 10-K Filing
- Compliance Restoration: On May 1, 2026, Celularity filed its 10-K report for the fiscal year 2025, successfully regaining compliance with Nasdaq Listing Rule 5250(c)(1), marking a significant advancement in the company's financial transparency.
- Strategic Restructuring: The company streamlined operations by out-licensing its biomaterials portfolio, realigning non-core personnel, and reducing liabilities by approximately $13 million, thereby enhancing operational efficiency and focusing on its core longevity and cell therapy platforms.
- Improved Financial Stability: These initiatives have significantly strengthened Celularity's balance sheet, enhancing its competitiveness in the market and supporting long-term value creation in the regenerative medicine sector.
- Future Outlook: The company is committed to leveraging the unique biology of the postpartum placenta to develop transformative therapies targeting aging and age-related diseases, showcasing its ambition and potential in the field of regenerative medicine.
See More
NEXGEL Appoints New CFO to Integrate Acquisition and Accelerate Growth
- Executive Appointment: NEXGEL has appointed Ian Blackman as Chief Financial Officer, leveraging his over 30 years of experience in luxury and consumer sectors to drive the integration of the Celularity acquisition, which is expected to enhance the company's financial foundation and operational efficiency.
- Acquisition Integration Strategy: Blackman's appointment coincides with NEXGEL's final agreement with Celularity, anticipated to strengthen the company's market competitiveness and drive long-term shareholder value through the integration of regenerative medicine assets.
- Performance Enhancement: During his tenure at McIntosh Group, Blackman successfully grew revenue by over 90% and EBITDA by over 335%, and his extensive financial management experience will provide robust support for NEXGEL's future growth.
- Market Opportunities: NEXGEL's hydrogel technology platform and expanding commercial footprint present significant growth opportunities for stakeholders, and Blackman's addition will help optimize financial reporting processes and enhance the company's overall financial performance.
See More
Celularity Receives Nasdaq Notice for Late Q1 2026 Filing
- Nasdaq Notice: Celularity received a Nasdaq notice for failing to timely file its Q1 2026 Form 10-Q, resulting in non-compliance with listing rules, although its stock continues to trade on Nasdaq.
- Compliance Plan Window: The company has a 60-day window until July 28 to submit a plan to regain compliance, and if accepted by Nasdaq, it may receive an extension of up to 180 days, with a final deadline around November 16, 2026.
- Proactive Measures: Celularity states it is actively working to file the delayed report and restore full compliance, indicating the company's commitment to addressing compliance issues.
- Stable Market Reaction: Despite facing compliance challenges, Celularity's stock has not experienced immediate impact in Nasdaq trading, reflecting market confidence in its future compliance plans.
See More
U.S. Stocks Rise Modestly; Three Stocks to Watch
- Market Performance: U.S. stocks rose modestly on the first trading day of May, with the S&P 500 gaining 0.3% to close above 7,200 for the first time, reflecting investor optimism despite a 0.3% dip in the Dow.
- Cantaloupe Stock Movement: Cantaloupe (CTLP) shares rose 1.6% in after-hours trading following the FTC's approval of 365 Retail's planned $848 million acquisition, which includes a required divestiture, potentially strengthening its market position.
- Celularity Stock Recovery: Celularity (CELU) shares gained 4.5% after regaining Nasdaq compliance, which is expected to boost investor confidence and attract more capital inflows into the company.
- Universal Logistics Earnings Miss: Universal Logistics (ULH) shares dipped 1.4% in extended trading after reporting Q1 GAAP EPS of -$0.13, missing consensus by $0.22, and operating revenue of $367.6 million, which fell short by $4.7 million, indicating operational challenges ahead.
See More
Celularity Regains Nasdaq Compliance with 10-K Filing
- Compliance Restoration: Celularity's filing of its 10-K annual report for the year ended December 31, 2025, has restored its compliance with Nasdaq listing rules, marking a significant advancement in the company's financial transparency and boosting investor confidence.
- Strategic Transformation Progress: CEO Robert Hariri noted that this filing represents an important milestone in the company's strategic transformation, reflecting positive developments in portfolio realignment and cost reductions aimed at enhancing overall operational efficiency.
- Financial Burden Reduction: By reducing liabilities by approximately $13 million, Celularity has further solidified its financial position, which will help the company focus resources on its core cell therapy and longevity programs, driving future growth.
- Personnel Adjustments: The company has also implemented personnel reductions to optimize human resource allocation, enhancing operational efficiency to maintain competitiveness in the highly competitive biotechnology sector.
See More
Celularity Regains Nasdaq Compliance After 10-K Filing
- Compliance Restoration: Celularity has successfully regained compliance with Nasdaq listing rules after filing its Form 10-K, ensuring the continued trading eligibility of its stock and avoiding potential delisting risks.
- Increased Financial Transparency: By submitting the 10-K, Celularity has enhanced the transparency of its financial reporting, boosting investor confidence and potentially attracting more investor interest in its future developments.
- Positive Market Reaction: The news of compliance restoration is likely to have a positive impact on Celularity's stock price, reinforcing market confidence in its business model and long-term growth potential.
- Strategic Implications: This compliance restoration not only secures the company's stable position in the capital markets but also provides more favorable conditions for future financing and business expansion.
See More
Celularity Regains Nasdaq Compliance with 10-K Filing
- Compliance Restoration: On May 1, 2026, Celularity filed its 10-K report for the fiscal year 2025, successfully regaining compliance with Nasdaq Listing Rule 5250(c)(1), marking a significant advancement in the company's financial transparency.
- Strategic Restructuring: The company streamlined operations by out-licensing its biomaterials portfolio, realigning non-core personnel, and reducing liabilities by approximately $13 million, thereby enhancing operational efficiency and focusing on its core longevity and cell therapy platforms.
- Improved Financial Stability: These initiatives have significantly strengthened Celularity's balance sheet, enhancing its competitiveness in the market and supporting long-term value creation in the regenerative medicine sector.
- Future Outlook: The company is committed to leveraging the unique biology of the postpartum placenta to develop transformative therapies targeting aging and age-related diseases, showcasing its ambition and potential in the field of regenerative medicine.
See More
NEXGEL Appoints New CFO to Integrate Acquisition and Accelerate Growth
- Executive Appointment: NEXGEL has appointed Ian Blackman as Chief Financial Officer, leveraging his over 30 years of experience in luxury and consumer sectors to drive the integration of the Celularity acquisition, which is expected to enhance the company's financial foundation and operational efficiency.
- Acquisition Integration Strategy: Blackman's appointment coincides with NEXGEL's final agreement with Celularity, anticipated to strengthen the company's market competitiveness and drive long-term shareholder value through the integration of regenerative medicine assets.
- Performance Enhancement: During his tenure at McIntosh Group, Blackman successfully grew revenue by over 90% and EBITDA by over 335%, and his extensive financial management experience will provide robust support for NEXGEL's future growth.
- Market Opportunities: NEXGEL's hydrogel technology platform and expanding commercial footprint present significant growth opportunities for stakeholders, and Blackman's addition will help optimize financial reporting processes and enhance the company's overall financial performance.
See More
